R&D channel feed

Ly­me vac­cine test com­ple­tion is pushed back by a year as Pfiz­er, Val­ne­va say they'll ad­just tri­al

3 years ago
Pharma

Ab­b­Vie says it has pos­i­tive mid-stage da­ta for Rin­voq in lu­pus, will move to PhI­II

3 years ago

FDA spells out how can­cer drug de­vel­op­ers can use one tri­al for both ac­cel­er­at­ed and full ap­provals

3 years ago

Rel­ma­da makes 'crit­i­cal changes' to PhI­II tri­al to try and save de­pres­sion drug

3 years ago

Hard pressed for cash, Cy­cle­ri­on looks for help fund­ing rare dis­ease drug

3 years ago

Brii Bio­sciences stops man­u­fac­tur­ing Covid-19 an­ti­body com­bo, plans to with­draw EUA re­quest

3 years ago
China
Coronavirus

Mod­er­na part­ners on non-vi­ral gene ther­a­py with Gen­er­a­tion Bio af­ter swing­ing gene edit­ing deals

3 years ago
Deals

Roy­al­ty Phar­ma hands off $100M up­front for PureTech roy­al­ty on Karuna's schiz­o­phre­nia hope­ful

3 years ago
Deals

FDA ap­proves Cidara's Rez­za­yo as an­ti­fun­gal treat­ment for can­didemia and in­va­sive can­didi­a­sis

3 years ago
FDA+

Sanofi, Re­gen­eron boast PhI­II win with Dupix­ent in COPD, clear­ing first bar for ex­pan­sion

3 years ago
Pharma

Re­gen­eron scores la­bel ex­pan­sion for cho­les­terol drug Evkeeza

3 years ago
Pharma

No­var­tis pulls the plug on UK-based car­dio­vas­cu­lar study

3 years ago

FDA re­jects Ab­b­Vie's in­fu­sion ther­a­py for Parkin­son's, re­quests more in­fo on pump de­vice

3 years ago
Pharma
FDA+

Quince Ther­a­peu­tics faces takeover bid from share­hold­er Echo Lake Cap­i­tal

3 years ago
Financing

Astel­las flesh­es out more PhI­II da­ta for Claudin 18.2 drug

3 years ago

No­var­tis touts sev­en years of dura­bil­i­ty da­ta for Zol­gens­ma

3 years ago

Roche and Lil­ly team up to de­vel­op blood test to de­tect ear­ly signs of Alzheimer's

3 years ago

89bio’s PhII da­ta add to quick suc­ces­sion of NASH read­outs as field seeks turn­around

3 years ago

Im­mat­ics an­nounces mul­ti­ple pipeline changes with lat­est fi­nan­cial re­sults

3 years ago

Roche un­veils long-term da­ta from piv­otal spinal mus­cu­lar at­ro­phy tri­al

3 years ago
Pharma

Al­tim­mune’s shares halved af­ter in­ter­im look at PhII weight loss drug da­ta

3 years ago

In­cyte touts mid-stage da­ta for new JAK in­hibitor but stops short of se­lect­ing PhI­II dose

3 years ago

So­bi's PhI­II gout win sets up a po­ten­tial ri­val­ry with fu­ture Am­gen as­set

3 years ago

FDA in­di­cates will­ing­ness to ap­prove Bio­gen ALS drug de­spite failed PhI­II study

3 years ago
FDA+
First page Previous page 949596979899100 Next page Last page
A service from the Financial Times